Anna Popova, head of the Federal Service to Monitor the Protection of Consumer Rights and Human Welfare, revealed that the Victor Research CenterVector“For virology and biotechnology, the second phase of clinical studies of the vaccine against the new corona virus has begun, confirming that all participating volunteers are in good health, according to the Russian TASS Agency.
She indicated that the Victor Research Center in Russia plans to launch the production of a Coronavirus vaccine.COVID-19“, In November, indicating that the second phase of clinical trials began today, and all the volunteers who were specially selected feel good health, and there are no reactions among those who were injected with the vaccine.
Earlier, the health watchdog that runs the Victor Research Center reported that 86 volunteers will receive the vaccine during the second phase of clinical trials..
Popova, the chief health doctor, told reporters that Russia, like any other country, must have several different vaccines against the new Corona virus, in response to a question about the difference between the vaccines developed by the Aesthetic Institute and the Victor Center.
“It is absolutely certain that in every country, including the Russian Federation, there must be several different vaccines, and this is what we are working on today,” she added..
On August 11, Russia became the first country in the world to register a vaccine against the coronavirus, which was named after itSputnik V , The preparation was developed by the National Aesthetic Institute for Epidemiological and Microbiology Research of the Russian Ministry of Health Care and passed clinical trials in June-July, based on a well-known platform previously used for other vaccines.
Kirill Dmitriev, head of the Russian Direct Investment Fund, said،(RDIF) That Russia has already received requests from 20 countries to supply it with two billion doses of the vaccine, meanwhile, on July 24, another developer received the center. Vector A permit from the Russian Ministry of Health Care to conduct clinical trials of a vaccine on volunteers, the first vaccination of a volunteer was on July 27, and 5 volunteers between the ages of 18 and 30 years participated in the first phase of the clinical trial.
The director general of the center, Rinat Maxiotov, confirmed that the launch of the vaccine is scheduled for November.